Mohamed Elmokadem Eman, Khaled Abou El Fadl Dina, Bassiouny Ahmed M, Mahmoud Maisa Mohamed Abd Elkhalik, Samy Mohammed, El Said Nouran Omar
Department of Pharmacy Practice and Clinical Pharmacy, Faculty of Pharmacy, Future University in Egypt, Cairo, Egypt.
Department of Radiodiagnosis, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Drug Des Devel Ther. 2025 Jul 14;19:6009-6024. doi: 10.2147/DDDT.S526188. eCollection 2025.
Post-cesarean section pain management remains a crucial challenge in obstetric care, with implications for maternal recovery, mother-child bonding, and long-term health outcomes. Quercetin, a naturally occurring flavonoid with anti-inflammatory and antioxidant properties, has shown promising analgesic effects in preclinical studies but has limited clinical evidence for acute pain management. This study aimed to assess the efficacy of preoperative Quercetin administration on acute post-operative pain following cesarean section.
In this prospective, double-blinded, randomized controlled trial, 80 patients undergoing elective cesarean section under spinal anaesthesia were randomly allocated to receive either 500 mg oral Quercetin (n=40) or matching placebo (n=40) one hour before surgery. The primary outcome was postoperative pain intensity assessed using a 10 cm Visual Analog Scale (VAS) at 2, 6, 12, and 24 hours after surgery. Secondary outcomes included time to first analgesic request, total morphine consumption, incidence of postoperative nausea and vomiting, time to physical activity initiation, functional activity, patient satisfaction, and adverse effects.
The Quercetin group demonstrated significantly lower VAS scores at all measured time points (p<0.001) and delayed time to first analgesic request (3.9±1.3 vs 2.73±0.78 hours, p<0.001) compared to the placebo group. Additionally, patients receiving Quercetin initiated physical activity significantly earlier (15.2±1.9 vs 19.03±2.66 hours, p<0.001) and reported higher satisfaction levels on postoperative day 2 (p=0.042). However, total morphine consumption, functional activity, incidence of nausea and vomiting, and hospital length of stay were comparable between groups, with no significant differences in adverse effects.
Preoperative administration of 500 mg Quercetin significantly reduced postoperative pain and delayed the need for rescue analgesia following cesarean section, allowing for earlier mobilization without increasing adverse effects. These findings suggest Quercetin may serve as a safe, effective adjunct in multimodal pain management protocols for cesarean delivery.
NCT06650891 (2024-10-21).
剖宫产术后疼痛管理仍是产科护理中的一项关键挑战,对产妇恢复、母婴亲密关系及长期健康结局均有影响。槲皮素是一种具有抗炎和抗氧化特性的天然类黄酮,在临床前研究中已显示出有前景的镇痛效果,但在急性疼痛管理方面的临床证据有限。本研究旨在评估术前给予槲皮素对剖宫产术后急性疼痛的疗效。
在这项前瞻性、双盲、随机对照试验中,80例接受脊髓麻醉下择期剖宫产的患者被随机分配,在手术前1小时接受500毫克口服槲皮素(n = 40)或匹配的安慰剂(n = 40)。主要结局是术后2、6、12和24小时使用10厘米视觉模拟量表(VAS)评估的术后疼痛强度。次要结局包括首次镇痛请求时间、吗啡总消耗量、术后恶心呕吐发生率、开始身体活动时间、功能活动、患者满意度及不良反应。
与安慰剂组相比,槲皮素组在所有测量时间点的VAS评分均显著更低(p < 0.001),且首次镇痛请求时间延迟(3.9±1.3对2.73±0.78小时,p < 0.001)。此外,接受槲皮素的患者开始身体活动的时间显著更早(15.2±1.9对19.03±2.66小时,p < 0.001),且在术后第2天报告的满意度更高(p = 0.042)。然而,两组之间的吗啡总消耗量、功能活动、恶心呕吐发生率及住院时间相当,不良反应无显著差异。
术前给予500毫克槲皮素可显著减轻剖宫产术后疼痛,并延迟急救镇痛需求,使患者能更早活动且不增加不良反应。这些发现表明槲皮素可能作为剖宫产多模式疼痛管理方案中的一种安全、有效的辅助药物。
NCT06650891(2024年10月21日)。